Subsequent Events (Tables)

3 Months Ended

Mar. 31, 2023

Subsequent Events [Abstract]

Schedule of remaining potential milestone payments

Under the terms of the GSK License Agreement, the Company received an upfront payment of $66.0 million for GSK to secure rights to the medicine. Remaining potential payments are milestone and royalty based, and are as follows (in millions):

Event	Milestone payments (up to)
From FDA acceptance of clinical protocol, commencement of Phase 3 study through NDA submission	$150.0 (in tranched milestones)
Total commercial milestone payments based on first sale (US/EU)	$150.0

Total potential sales milestone payments	$225.0
Royalties	Low-single digit to low-double digit (if sales exceed $1.0 billion) tiered royalties on net product sales